Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

U.S. judge limits evidence in trial over Roundup cancer claims

Stock Markets Jan 03, 2019 09:45PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris 2/2
 
BAYGN
-0.35%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MON
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Tina Bellon

(Reuters) - A federal judge overseeing lawsuits alleging Bayer (DE:BAYGN) AG's glyphosate-based weed killer causes cancer has issued a ruling that could severely restrict evidence that the plaintiffs consider crucial to their cases.

U.S. District Judge Vince Chhabria in San Francisco in an order on Thursday granted Bayer unit Monsanto's request to split an upcoming trial into two phases. The order initially bars lawyers for plaintiff Edwin Hardeman from introducing evidence that the company allegedly attempted to influence regulators and manipulate public opinion.

Thursday's order applies to Hardeman's case, which is scheduled to go to trial on Feb. 25, and two other so-called bellwether trials which will help determine the range of damages and define settlement options for the rest of the 620 Roundup cases before Chhabria.

But Hardeman's lawyers contended that such evidence, including internal Monsanto (NYSE:MON) documents, showed the company's misconduct and were critical to California state court jury's August 2018 decision to award $289 million in a similar case. The verdict sent Bayer shares tumbling though the award was later reduced to $78 million and is under appeal.

Under Chhabria's order, evidence of Monsanto's alleged misconduct would be allowed only if glyphosate was found to have caused Hardeman's cancer and the trial proceeded to a second phase to determine Bayer's liability.

Bayer denies allegations that glyphosate causes cancer, saying decades of independent studies have shown the world's most widely used weed killer to be safe for human use.

But the company faces more than 9,300 U.S. lawsuits over Roundup's safety in state and federal courts across the country.

Bayer in a statement welcomed Chhabria's decision.

"The court's decision to keep the focus of the trial on the extensive science relevant to human health is encouraging," the company said.

Aimee Wagstaff, one of Hardeman's lawyers, in a statement said she was confident the jurors will find Roundup caused the man's cancer and proceed to the second phase.

Hardeman's attorneys had opposed proposals to split up the trial on the grounds that their scientific evidence allegedly showing glyphosate causes cancer was inextricably linked to Monsanto's alleged wrongful conduct.

Bayer has also asked that some of the plaintiffs' evidence on causation, specifically a finding by the World Health Organization's cancer unit that glyphosate is "probably carcinogenic," be excluded in the first phase because it has no basis in science.

Chhabria, who has previously expressed skepticism of that finding, on Thursday said he would soon decide to which degree he would allow it to be introduced at trial.

The assessment is central to the plaintiffs' claims, as other regulatory agencies, including the U.S. Environmental Protection Agency, have determined glyphosate likely does not cause cancer.

U.S. judge limits evidence in trial over Roundup cancer claims
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Norm Norm
Norm Norm Jan 03, 2019 10:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Crooked judges make crooked decisions
Mike Roland
Mike Roland Jan 03, 2019 10:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
which party nominated him?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email